ADMA Biologics ADMA Preferred stock, capital shares reserved for future issuance (in shares)
Preferred stock, capital shares reserved for future issuance (in shares) at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares)?
- ADMA Biologics (ADMA) reported preferred stock, capital shares reserved for future issuance (in shares) of 10M in Q1 2026.
- How has ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares) changed year-over-year?
- ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares) decreased by 0.0% year-over-year, from 10M to 10M.
- What is the long-term trend for ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares)?
- Over 5 years (2020 to 2025), ADMA Biologics's preferred stock, capital shares reserved for future issuance (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
- What does preferred stock, capital shares reserved for future issuance (in shares) mean?
- This represents the number of preferred stock shares set aside for potential future issuance, such as for conversion of debt or future financing rounds. It provides insight into the company's potential equity dilution and capital structure flexibility.